Kyverna Therapeutics, Inc. Net Income Loss

Quick Answer

Kyverna Therapeutics, Inc. reported Net Income Loss of -$161.31 million for the year ending 2025.

  • Kyverna Therapeutics, Inc. showed a decrease of -26.5% in Net Income Loss from 2024 to 2025.
  • This data is from Kyverna Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
  • XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 3 years of available data (2023 to 2025), Kyverna Therapeutics, Inc.'s Net Income Loss has declined by 167.2%.
  • Historical annual values: Fiscal year 2025: -$161.31 million | Fiscal year 2024: -$127.48 million | Fiscal year 2023: -$60.37 million.
  • Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: